- Report
- March 2025
- 132 Pages
Global
From €3973EUR$4,365USD£3,374GBP
€4414EUR$4,850USD£3,749GBP
- Report
- May 2022
- 330 Pages
Global
From €2731EUR$3,000USD£2,319GBP
- Report
- February 2022
- 360 Pages
United States
From €3277EUR$3,600USD£2,783GBP
- Report
- April 2021
China
From €2366EUR$2,600USD£2,010GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,126GBP
- Report
- January 2022
- 92 Pages
Global
From €6326EUR$6,950USD£5,373GBP
- Report
- January 2022
- 200 Pages
Global
From €6826EUR$7,500USD£5,798GBP
- Report
- October 2023
- 145 Pages
Global
From €2867EUR$3,150USD£2,435GBP
- Report
- April 2024
- 180 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- October 2023
- 185 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- April 2023
- 130 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- August 2022
- 115 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- August 2022
- 118 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- October 2023
- 68 Pages
Global
From €9097EUR$9,995USD£7,727GBP
- Report
- September 2023
- 65 Pages
Global
From €9097EUR$9,995USD£7,727GBP
- Report
- October 2021
- 57 Pages
Global
From €9097EUR$9,995USD£7,727GBP
- Report
- February 2023
- 27 Pages
Global
€11150EUR$12,250USD£9,470GBP
- Report
- January 2019
- 40 Pages
Global
From €9102EUR$10,000USD£7,731GBP
- Report
- January 2019
- 18 Pages
Global
From €9102EUR$10,000USD£7,731GBP
- Report
- April 2018
United States
From €7277EUR$7,995USD£6,181GBP

Rituxan (rituximab) is a monoclonal antibody used to treat a variety of immune disorders, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and granulomatosis with polyangiitis. It is used in combination with other drugs to treat these conditions. Rituxan works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response.
Rituxan is a biologic drug, meaning it is made from living cells. It is administered intravenously and is typically given in two doses, two weeks apart. The drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain immune disorders.
Rituxan is a widely used drug in the immune disorders market. It is one of the most prescribed drugs for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. It is also used off-label to treat other conditions, such as systemic lupus erythematosus.
Some companies in the Rituxan market include Genentech, Biogen, and Roche. Show Less Read more